The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

A secondary heart attack could be prevented by replacing 30 minutes of sedentary behavior with light-intensity or moderate-to ...

An estimated 32 million people globally have heart failure with reduced ejection fraction, a condition where the lower left ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.